Factor | Total cohort (n = 103) | Peg-IFN + RBV (n = 19) | Peg-IFN + RBV + TPV (n = 23) | IFN-free DAA (n = 61) | P value* |
---|---|---|---|---|---|
Age in years, mean (SD) | 49.7 (9.3) | 43.6 (12.1) | 45.3 (7.8) | 53.2 (7.0) | < 0.001 |
Sex | |||||
Female | 7 (6.8%) | 2 (11%) | 3 (13%) | 2 (3%) | 0.17 |
Male | 96 (93.2%) | 17 (89%) | 20 (87%) | 59 (97%) | |
Race | |||||
Non-white | 27 (26.2%) | 5 (26%) | 6 (26%) | 16 (26%) | 1.00 |
White | 76 (73.8%) | 14 (74%) | 17 (74%) | 45 (74%) | |
Ethnicity | |||||
Not hispanic | 85 (82.5%) | 14 (74%) | 17 (74%) | 54 (89%) | 0.14 |
Hispanic | 18 (17.5%) | 5 (26%) | 6 (26%) | 7 (11%) | |
HIV risk factor | |||||
MSM | 24 (23.3%) | 4 (21%) | 3 (13%) | 17 (28%) | 0.55 |
Heterosexual | 1 (1.0%) | 0 (0%) | 0 (0%) | 1 (2%) | |
Hemophilia | 6 (5.8%) | 0 (0%) | 3 (13%) | 3 (5%) | |
MSM + IDU | 45 (43.7%) | 11 (58%) | 11 (48%) | 23 (38%) | |
Heterosexual IDU | 27 (26.2%) | 4 (21%) | 6 (26%) | 17 (28%) | |
CD4 + in cells/mm3, median (IQR) | 476.0 (341, 693) | 607.0 (419, 719) | 584.0 (426, 772) | 417 (306, 598) | 0.045 |
HIV viral load in copies/mL | |||||
≤ 50 | 94 (91.3%) | 17 (89%) | 20 (87%) | 59 (97%) | 1.00 |
> 50 | 9 (8.7%) | 5 (26%) | 6 (26%) | 16 (26%) | |
HCV viral load in millions IU/L, median (IQR) | 2.0 (0.4, 5.8) | 3.8 (0.3, 9.7) | 3.6 (1.2, 17) | 1.3 (0.4, 3.5) | 0.017 |
HCV genotype | |||||
1/1A/1B | 86 (83.5%) | 13 (68%) | 23 (100%) | 50 (83%) | 0.014 |
2 | 4 (3.8%) | 1 (5%) | 0 (0%) | 3 (5%) | |
3 | 11 (10.7%) | 5 (26%) | 0 (0%) | 6 (10%) | |
4 | 2 (1.9%) | 0 (0%) | 0 (0%) | 2 (3%) | |
HCV treatment history | |||||
Naïve | 80 (77.7%) | 19 (100%) | 16 (70%) | 45 (74%) | 0.19 |
IFN-intolerant | 6 (5.8%) | 0 (0%) | 1 (4%) | 5 (8%) | |
Relapser | 10 (9.7%) | 0 (0%) | 5 (22%) | 5 (8%) | |
Null responder | 6 (5.8%) | 0 (0%) | 1 (4%) | 5 (8%) | |
Cure but reinfected | 1 (1.0%) | 0 (0%) | 0 (0%) | 1 (2%) | |
Cirrhosis status | |||||
Non-cirrhotic | 70 (68.0%) | 17 (89%) | 17 (74%) | 36 (59%) | 0.032 |
Cirrhotic | 33 (32.0%) | 2 (11%) | 6 (26%) | 25 (41%) | |
Prior decompensation or CPS > B | |||||
Compensated cirrhosis | 20 (19.4%) | 2 (11%) | 4 (17%) | 14 (23%) | 0.13 |
Prior decompensated cirrhosis | 13 (12.6%) | 0 (0%) | 2 (9%) | 11 (18%) | |
Non-cirrhotic | 70 (68.0%) | 17 (89%) | 17 (74%) | 36 (59%) | |
SVR on treatment 1 | |||||
Yes | 78 (76.5%) | 12 (63%) | 13 (57%) | 53 (88%) | 1.00 |
No, null response | 7 (6.9%) | 2 (11%) | 5 (22%) | 0 (0%) | |
No, relapse | 4 (3.9%) | 3 (16%) | 0 (0%) | 1 (2%) | |
No, sides effects/adverse events | 9 (8.8%) | 2 (11%) | 5 (22%) | 2 (3%) | |
No, died during treatment | 4 (3.9%) | 0 (0%) | 0 (0%) | 4 (7%) | |
Discontinuation due to severe adverse events (1st regimen) | |||||
No | 93 (91.2%) | 17 (89%) | 18 (78%) | 58 (97%) | 0.021 |
Yes | 9 (8.8%) | 2 (11%) | 5 (22%) | 2 (3%) | |
No. HCV-SI observations, median (IQR) | 7.0 (4.0, 12.0) | 8.0 (6.0, 15.0) | 15.0 (11.0, 20.0 | 5.0 (4.0, 7.0) | < 0.001 |
Barriers to care | |||||
Ongoing drugs/alcohol use | 30 (29%) | 8 (42%) | 7 (30%) | 15 (25%) | 0.34 |
Active psychiatric disease | 28 (27%) | 8 (42%) | 6 (26%) | 14 (23%) | 0.26 |
Unstable housing | 5 (5%) | 1 (5%) | 3 (13%) | 1 (2%) | 0.10 |